ES2962439T3 - Agente terapéutico que activa la función mTORC1 para su uso en el tratamiento de la enfermedad de Huntington - Google Patents
Agente terapéutico que activa la función mTORC1 para su uso en el tratamiento de la enfermedad de Huntington Download PDFInfo
- Publication number
- ES2962439T3 ES2962439T3 ES15876243T ES15876243T ES2962439T3 ES 2962439 T3 ES2962439 T3 ES 2962439T3 ES 15876243 T ES15876243 T ES 15876243T ES 15876243 T ES15876243 T ES 15876243T ES 2962439 T3 ES2962439 T3 ES 2962439T3
- Authority
- ES
- Spain
- Prior art keywords
- aav
- therapeutic agent
- mice
- rhes
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0085—Brain, e.g. brain implants; Spinal cord
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y306/00—Hydrolases acting on acid anhydrides (3.6)
- C12Y306/05—Hydrolases acting on acid anhydrides (3.6) acting on GTP; involved in cellular and subcellular movement (3.6.5)
- C12Y306/05002—Small monomeric GTPase (3.6.5.2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Microbiology (AREA)
- Virology (AREA)
- Psychology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462098085P | 2014-12-30 | 2014-12-30 | |
| PCT/US2015/068034 WO2016109649A1 (en) | 2014-12-30 | 2015-12-30 | Methods and compositions for treating brain diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2962439T3 true ES2962439T3 (es) | 2024-03-19 |
Family
ID=56285031
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES15876243T Active ES2962439T3 (es) | 2014-12-30 | 2015-12-30 | Agente terapéutico que activa la función mTORC1 para su uso en el tratamiento de la enfermedad de Huntington |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US11612641B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3240577B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP6782701B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR102618947B1 (cg-RX-API-DMAC7.html) |
| CN (1) | CN107405414A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2015374043B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112017013674A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2971687C (cg-RX-API-DMAC7.html) |
| ES (1) | ES2962439T3 (cg-RX-API-DMAC7.html) |
| SG (1) | SG11201704829QA (cg-RX-API-DMAC7.html) |
| WO (1) | WO2016109649A1 (cg-RX-API-DMAC7.html) |
| ZA (1) | ZA201704327B (cg-RX-API-DMAC7.html) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114717264A (zh) | 2014-11-14 | 2022-07-08 | 沃雅戈治疗公司 | 治疗肌萎缩性侧索硬化(als)的组合物和方法 |
| KR20230145206A (ko) | 2014-11-14 | 2023-10-17 | 보이저 테라퓨틱스, 인크. | 조절성 폴리뉴클레오티드 |
| WO2016109649A1 (en) | 2014-12-30 | 2016-07-07 | University Of Iowa Research Foundation | Methods and compositions for treating brain diseases |
| US10584337B2 (en) | 2016-05-18 | 2020-03-10 | Voyager Therapeutics, Inc. | Modulatory polynucleotides |
| IL297576B2 (en) | 2016-05-18 | 2024-02-01 | Voyager Therapeutics Inc | Compositions and methods of treating huntington's disease |
| CL2016003282A1 (es) * | 2016-12-21 | 2017-08-18 | Univ Chile | Virus aav/igf2, método de tratamiento genético y su uso en enfermedades relacionadas con mal plegamiento de proteínas tal como la enfermedad de huntington |
| WO2018132791A1 (en) * | 2017-01-16 | 2018-07-19 | The Regents Of The University Of California | Treatment of neurodegenerative conditions by disruption of rhes |
| MX2019013172A (es) | 2017-05-05 | 2020-09-07 | Voyager Therapeutics Inc | Composiciones y metodos para tratar la enfermedad de huntington. |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050255086A1 (en) | 2002-08-05 | 2005-11-17 | Davidson Beverly L | Nucleic acid silencing of Huntington's Disease gene |
| US20050009112A1 (en) | 2003-03-07 | 2005-01-13 | Fred Hutchinson Cancer Research Center, Office Of Technology Transfer | Methods for identifying Rheb effectors as lead compounds for drug development for diabetes and diseases associated with abnormal cell growth |
| JP2008539276A (ja) | 2005-04-27 | 2008-11-13 | ユニバーシティ オブ フロリダ リサーチ ファウンデーション,インコーポレイティド | ヒト疾患に関連する変異体タンパク質の分解能を改善するための材料及び方法 |
| KR101286870B1 (ko) * | 2009-11-30 | 2013-07-16 | (주)아모레퍼시픽 | 황기 추출물을 포함하는 대사 촉진 조성물 |
| SG11201401716XA (en) * | 2011-10-28 | 2014-05-29 | Novartis Ag | Novel purine derivatives and their use in the treatment of disease |
| WO2013067125A1 (en) * | 2011-11-01 | 2013-05-10 | Children's Medical Center Corporation | Co-activation of mtor and stat3 pathways to promote neuronal survival and regeneration |
| CN104080786A (zh) | 2011-11-08 | 2014-10-01 | 因特利凯有限责任公司 | 使用多种药剂的治疗方案 |
| US9095521B2 (en) * | 2012-02-02 | 2015-08-04 | Washington University | Methods for improving muscle strength |
| KR101626526B1 (ko) | 2014-10-30 | 2016-06-02 | 경북대학교 산학협력단 | hRheb를 유효성분으로 포함하는 허혈성 뇌질환의 예방 또는 치료용 조성물 |
| WO2016109649A1 (en) | 2014-12-30 | 2016-07-07 | University Of Iowa Research Foundation | Methods and compositions for treating brain diseases |
-
2015
- 2015-12-30 WO PCT/US2015/068034 patent/WO2016109649A1/en not_active Ceased
- 2015-12-30 EP EP15876243.5A patent/EP3240577B1/en active Active
- 2015-12-30 BR BR112017013674A patent/BR112017013674A2/pt not_active Application Discontinuation
- 2015-12-30 US US15/540,746 patent/US11612641B2/en active Active
- 2015-12-30 CN CN201580077153.9A patent/CN107405414A/zh active Pending
- 2015-12-30 KR KR1020177020915A patent/KR102618947B1/ko active Active
- 2015-12-30 ES ES15876243T patent/ES2962439T3/es active Active
- 2015-12-30 SG SG11201704829QA patent/SG11201704829QA/en unknown
- 2015-12-30 CA CA2971687A patent/CA2971687C/en active Active
- 2015-12-30 AU AU2015374043A patent/AU2015374043B2/en active Active
- 2015-12-30 JP JP2017534822A patent/JP6782701B2/ja active Active
-
2017
- 2017-06-26 ZA ZA2017/04327A patent/ZA201704327B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2971687C (en) | 2024-05-28 |
| JP2018502112A (ja) | 2018-01-25 |
| CA2971687A1 (en) | 2016-07-07 |
| AU2015374043B2 (en) | 2021-05-13 |
| JP6782701B2 (ja) | 2020-11-11 |
| EP3240577B1 (en) | 2023-07-05 |
| AU2015374043A1 (en) | 2017-07-13 |
| ZA201704327B (en) | 2025-02-26 |
| KR20170098931A (ko) | 2017-08-30 |
| US20180000907A1 (en) | 2018-01-04 |
| HK1245127A1 (en) | 2018-08-24 |
| BR112017013674A2 (pt) | 2018-02-06 |
| US11612641B2 (en) | 2023-03-28 |
| NZ733014A (en) | 2024-05-31 |
| EP3240577A1 (en) | 2017-11-08 |
| SG11201704829QA (en) | 2017-07-28 |
| KR102618947B1 (ko) | 2023-12-27 |
| CN107405414A (zh) | 2017-11-28 |
| EP3240577A4 (en) | 2018-07-25 |
| WO2016109649A1 (en) | 2016-07-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11612641B2 (en) | Method for treating Huntingtons's disease | |
| US20220333131A1 (en) | Modulatory polynucleotides | |
| AU2018352236B2 (en) | Treatment of amyotrophic lateral sclerosis (ALS) | |
| US11155817B2 (en) | Therapeutic for treatment of diseases including the central nervous system | |
| EP3963055A1 (en) | Vectorized antibodies (vab) and uses thereof | |
| AU2018261003A1 (en) | Compositions and methods of treating Huntington's Disease | |
| JP2025011130A (ja) | ネフローゼ症候群を処置するためのaav遺伝子療法 | |
| JP2006521825A (ja) | rAAV導入を高めるための化合物および方法 | |
| CN104540952A (zh) | 用于治疗淀粉状蛋白沉积的方法和组合物 | |
| WO2016106458A1 (es) | Virus aav/xbp1s-ha, método de tratamiento genético y su uso en la optimización y mejoramiento de las capacidades cognitivas, de memoria y de aprendizaje | |
| US20240343768A1 (en) | Gene therapy for tuberous sclerosis | |
| Merjane et al. | Molecular mechanisms of amyotrophic lateral sclerosis as broad therapeutic targets for gene therapy applications utilizing adeno‐associated viral vectors | |
| AU2025275257A1 (en) | Expression vector for cholesterol 24-hydrolase in therapy of amyotrophic lateral sclerosis | |
| Luo et al. | P2Y1R silencing in astrocytes protected neuroinflammation and cognitive decline in a mouse model of Alzheimer's disease | |
| HK1245127B (en) | Therapeutic agent that activates mtorc1 function for use in treating huntington's disease | |
| Blanch García | AAV-mediated expression of Secreted Klotho as a therapeutic strategy for Alzheimer's disease | |
| WO2025015328A2 (en) | Increasing nfe2l1 activity or expression as therapy for eye disorders | |
| Afonso-Reis et al. | The stress granule protein G3BP1 alleviates spinocerebellar ataxia-associated deficits | |
| He | Peripheral gene therapy for the treatment of Alzheimer’s disease | |
| HK40052708B (en) | Expression vector for cholesterol 24-hydrolase in therapy of amyotrophic lateral sclerosis | |
| JP2022531177A (ja) | 神経変性障害を治療するための方法 | |
| HK40052708A (zh) | 用於肌萎缩性侧索硬化疗法中的胆固醇24-羟化酶的表达载体 | |
| WO2018112672A1 (es) | Virus aav/igf2, metodo de tratamiento genetico y su uso en enfermedades relacionadas con mal plegamiento de proteinas tal como la enfermedad de huntington |